Nervgen Pharma NGEN
NASDAQ NGEN
$2.16 +0.03 (+1.41%)
At close: Sep 10, 2026 · 4:00 PM EDT

Nervgen Pharma (NGEN) Cash from Financing Activities (2025 - 2026)

Nervgen Pharma's (NGEN) quarterly Cash from Financing Activities came in at $56.5 million in Q2 2026, up 1547.09% year-over-year from $3.4 million in Q2 2025, and up 2687.16% quarter-over-quarter from $2.0 million in Q1 2026.

Analysis

Nervgen Pharma (NGEN) Cash from Financing Activities (2025 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Cash from Financing Activities for 2 consecutive years, with $56.5 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Cash from Financing Activities rose 1547.09% year-over-year to $56.5 million in Q2 2026; TTM through Jun 2026 was $62.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $17.0 million, up 2.8% from the prior year.
  • Cash from Financing Activities was $56.5 million for Q2 2026 at Nervgen Pharma, up from $2.0 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $56.5 million in Q2 2026 and troughed at $888133.6 in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 36.24 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 1.30 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -181.51 Mn
10 Nervgen Pharma 156.23 Mn 156.23 Mn - 56.49 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 56.49 Mn
Mar 31, 2026 2.03 Mn
Jun 30, 2025 3.43 Mn
Mar 31, 2025 888,133.63